{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=60",
    "query": {
      "intervention": "Normal protein",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 2507,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T05:32:24.141Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01194271",
      "title": "Neoadjuvant Ipilimumab in Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2010-09",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194271"
    },
    {
      "nct_id": "NCT04784767",
      "title": "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride, USP, for injection (0.9% NaCl)",
          "type": "DRUG"
        },
        {
          "name": "50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-05",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784767"
    },
    {
      "nct_id": "NCT03440567",
      "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-06-08",
      "completion_date": "2024-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03440567"
    },
    {
      "nct_id": "NCT04732000",
      "title": "Oxidative Stress and Surgical Recovery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Surgical Recovery",
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "N-acetyl cysteine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-07-01",
      "completion_date": "2023-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732000"
    },
    {
      "nct_id": "NCT00482807",
      "title": "Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "goserelin",
          "type": "DRUG"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "19 Years to 120 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2004-08-31",
      "completion_date": "2010-03-09",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00482807"
    },
    {
      "nct_id": "NCT05210504",
      "title": "Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "L-Lysine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 23,
      "start_date": "2022-03-09",
      "completion_date": "2023-01-27",
      "has_results": true,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05210504"
    },
    {
      "nct_id": "NCT00589472",
      "title": "Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage I Prostate Cancer",
        "Stage IIA Prostate Cancer",
        "Stage IIB Prostate Cancer",
        "Stage III Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2007-11",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589472"
    },
    {
      "nct_id": "NCT00075192",
      "title": "CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "CP-675,206 and leuprolide acetate and bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate and bicalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2004-03",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-06",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 11,
      "location_summary": "La Masa, California • Washington D.C., District of Columbia • Gallatin, Tennessee + 5 more",
      "locations": [
        {
          "city": "La Masa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gallatin",
          "state": "Tennessee"
        },
        {
          "city": "Hermitage",
          "state": "Tennessee"
        },
        {
          "city": "Lebanon",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075192"
    },
    {
      "nct_id": "NCT02031211",
      "title": "TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "CRPS",
        "Chronic Regional Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "10 Years to 17 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-10-14",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02031211"
    },
    {
      "nct_id": "NCT06058377",
      "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "HER2-Negative Breast Carcinoma",
        "Hormone Receptor-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Genetic Testing",
          "type": "OTHER"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3680,
      "start_date": "2023-11-27",
      "completion_date": "2032-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-03T05:32:24.141Z",
      "location_count": 561,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 431 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06058377"
    }
  ]
}